Ph.D., Cornell University Graduate School of Medical Sciences, 1991
M.D., Cornell University Medical College, 1992
email@example.com | 516-734-8976 (p)
With joint appointments at CSHL and Northwell Health, I am working to expand clinical cancer research at our institutions to provide new treatments for patients as well as greater insight into the biology of this complex set of diseases. In my own research, I am collaborating on research in soft-tissue and bone sarcomas to better understand the cancer microenvironment and epigenetics, targeting molecular weaknesses to halt cancer growth.
Robert Maki is interested in applying basic research discoveries in the clinic to treat patients with sarcomas and other neoplasms of soft-tissue and bone. Pathologists recognize more than 70 types of sarcoma, but using molecular characteristics (changes in DNA sequence like translocations or mutations), there is even greater heterogeneity. Nonetheless, commonalities of this cell lineage provide some entry points for investigational therapies. Dr. Maki is working to exploit these molecular changes to inhibit growth and proliferation of sarcoma.
Dr. Maki also maintains a particular interest in angiosarcoma, leiomyosarcoma and desmoid tumors as manifestations of the interplay of the microenvironment with cancer. He is also exploring the common pathways in metabolism and epigenetics in the hope that they may provide useful tools to circumvent the well-appreciated genetic heterogeneity of most cancers.
In developing the Center for New Cancer Therapies (CNCT) at Northwell Health Cancer Institute, Dr. Maki facilitates the translation of basic research at CSHL into the clinics of partner institutions, in particular Northwell Health’s Monter Cancer Center. Dr. Maki brings significant expertise in the interplay between clinical and basic research: he has written and conducted phase I-II-III trials in soft tissue and bone tumors at his home institutions and via collaborative efforts such as SARC (Sarcoma Alliance for Research through Collaboration), and will apply that knowledge as CSHL and Northwell Health expand their clinical trials.
2014 Fellow, American College of Physicians
2013 Nobility in Science Award, Sarcoma Foundation of America
2009 NCI Clinical Investigator Team Leadership Award
2007 Byrne Fund Award, Memorial Sloan-Kettering Cancer Center
Heinrich, M. and Rankin, C. and Blanke, C. D. and Demetri, G. D. and Borden, E. C. and Ryan, C. W. and von Mehren, M. and Blackstein, M. E. and Priebat, D. A. and Tap, W. D. and Maki, R. G. and Corless, C. L. and Fletcher, J. A. and Owzar, K. and Crowley, J. J. and Benjamin, R. S. and Baker, L. H. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol, 3(7) pp. 944-952.
Pappo, A. S. and Vassal, G. and Crowley, J. J. and Bolejack, V. and Hogendoorn, P. C. and Chugh, R. and Ladanyi, M. and Grippo, J. F. and Dall, G. and Staddon, A. P. and Chawla, S. P. and Maki, R. G. and Araujo, D. M. and Geoerger, B. and Ganjoo, K. and Marina, N. and Blay, J. Y. and Schuetze, S. M. and Chow, W. A. and Helman, L. J. (2014) A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer, 120(16) pp. 2448-56.
Farid, M. and Ahn, L. and Brohl, A. and Cioffi, A. and Maki, R. G. (2014) Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?. Sarcoma, 2014 pp. 617102.
Maki, R. G. and Moraco, N. and Antonescu, C. R. and Hameed, M. and Pinkhasik, A. and Singer, S. and Brennan, M. F. (2013) Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. Ann Surg Oncol, 20(11) pp. 3377-83.Additional materials of the author at
CSHL Institutional Repository